Prot# INCB 8721 RVT-203: A Placebo-Controlled, Double-Blind, Parallel Dose Group Study Exploring the Safety, Tolerability, & Virological Effect of 50, 100, & 200mg Reverset? (RVT) in HIV-Infected Antiretroviral Therapy-Experienced Subjects When Used in Co

Project: Research project

Project Details

StatusFinished
Effective start/end date9/8/04 → 4/13/07

Funding

  • Quintiles, Inc. (INCB 8721 RVT-203)
  • Incyte Corporation (INCB 8721 RVT-203)